IO Biotech (IOBT) Stock Price, News & Analysis

Company Overview

IO Biotech ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors.

Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma. The company’s pipeline also explores combination regimens that pair its vaccine technology with established checkpoint inhibitors to enhance therapeutic efficacy. Research and development activities are conducted in Denmark, with ongoing collaborations and trial sites across Europe and North America to support global patient access.

IO Biotech is led by an experienced management team with deep expertise in immunology, oncology drug development and regulatory affairs. The company’s strategic focus remains on translating its innate immune-priming technology into differentiated cancer treatments and expanding its clinical footprint through partnerships and investigator-initiated studies.

Key Stats

• Today's Range: $1.90 to $2.08
• 50-Day Range: $1.05 to $2.40
• 52-Week Range: $0.66 to $2.79
• Volume: 1.10 million shs
• Average Volume: 3.64 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

IO Biotech Stock Analysis - MarketRank™

IO Biotech scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

IO Biotech has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

IO Biotech has a consensus price target of $8.00, representing about 284.6% upside from its current price of $2.08.

Amount of Analyst Coverage

IO Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IO Biotech are expected to grow in the coming year, from ($1.35) to ($1.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IO Biotech is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IO Biotech is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IO Biotech has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.50% of the float of IO Biotech has been sold short.

Short Interest Ratio / Days to Cover

IO Biotech has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IO Biotech has recently decreased by 16.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IO Biotech does not currently pay a dividend.

Dividend Growth

IO Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.50% of the float of IO Biotech has been sold short.

Short Interest Ratio / Days to Cover

IO Biotech has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IO Biotech has recently decreased by 16.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.65

News Sentiment

IO Biotech has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for IO Biotech this week, compared to 2 articles on an average week.

Search Interest

26 people have searched for IOBT on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added IO Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IO Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.80% of the stock of IO Biotech is held by insiders.

Percentage Held by Institutions

54.76% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IOBT Stock Analysis - Frequently Asked Questions

How have IOBT shares performed this year?

IO Biotech's stock was trading at $0.92 on January 1st, 2025. Since then, IOBT stock has increased by 126.1% and is now trading at $2.08.

How were IO Biotech's earnings last quarter?

IO Biotech, Inc. (NASDAQ:IOBT) released its quarterly earnings results on Thursday, August, 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.05.

When did IO Biotech IPO?

IO Biotech (IOBT) raised $111 million in an IPO on Friday, November 5th 2021. The company issued 7,150,000 shares at $14.00-$17.00 per share.

Who are IO Biotech's major shareholders?

Top institutional shareholders of IO Biotech include Bank of America Corp DE, Marex Group plc, XTX Topco Ltd and NewEdge Advisors LLC (0.04%). Insiders that own company stock include Holdings A/S Novo, Vivo Capital Ix, Llc, Amy Sullivan, Mai-Britt Zocca, Heidi Hunter and Brian Burkavage.
View institutional ownership trends.

How do I buy shares of IO Biotech?

Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IO Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IO Biotech investors own include COMPASS Pathways (CMPS), Nkarta (NKTX), PayPal (PYPL), AbCellera Biologics (ABCL), atai Life Sciences (ATAI), Meta Platforms (META) and

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IOBT
• CIK: 1865494
• Web: www.iobiotech.com
• Phone: 45-7070-2980
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IO Biotech: $8.00
• High Price Target: $12.00
• Low Price Target: $4.00
• Potential Upside/Downside: +284.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$95.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -281.82%
• Return on Assets: -169.29%

Debt

• Debt-to-Equity Ratio: 4.22
• Current Ratio: 1.96
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 2.93

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.41